Clinical Trial

Effect of Food of NTQ5082 in Healthy Subjects

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 19, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
NTQ5082 capsule is a small molecule CFB factor inhibitor. The study is a randomized, open label, two sequence, two period, double crossover-design phase 1 clinical trial to evaluate the food effect on PK after a single oral administration of NTQ5082 capsules and the safety and tolerability of single oral administration of NTQ5082 capsules on an empty stomach (i.e, fasting) as well as after a meal (i.e. fed) in healthy subjects
Trial Details
NCT Number NCT06558656
Lead Sponsor Nanjing Chia-tai Tianqing Pharmaceutical
Conditions Complement-mediated Hemolytic Diseases
Enrollment 12 participants
Start Date 2024-08
Primary Completion 2024-12 (estimated)
Study Completion 2025-02 (estimated)
Updated on ClinicalTrials.gov 2024-08-19